Poloxipan
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research[1].
Product Specifications
CAS Number
1239513-63-3
UNSPSC
12352005
Target
PIN1; Polo-like Kinase (PLK) ; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; JAK/STAT Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/poloxipan.html
Smiles
O=C1N2C(S/C1=C\C3=C(C=CC(Br)=C3)OC)=NC(C(C)=N2)=O
Molecular Formula
C14H10BrN3O3S
Molecular Weight
380.22
References & Citations
[1]Kumar S, et al. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Biomed Res Int. 2015;2015:705745.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (MUC1/2980R), CF488A conjugate, 0.1mg/mL
